Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Solifenacin succinate
Drug ID BADD_D02054
Description Solifenacin is a competitive muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency.[L7511] It has a long duration of action as it is usually taken once daily.[L7511] Solifenacin was granted FDA approval on 19 November 2004.[L7511]
Indications and Usage Solifenacin tablets are indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency.[L7511]
Marketing Status approved
ATC Code G04BD08
DrugBank ID DB01591
KEGG ID D01269
MeSH ID D000069464
PubChem ID 216457
TTD Drug ID D0L4YD
NDC Product Code 51248-151; 0527-1933; 0591-3795; 71335-1729; 65862-800; 51407-472; 60505-4702; 62332-193; 63629-8869; 69539-050; 0591-3796; 42185-7071; 51407-228; 62332-192; 67877-528; 69238-1309; 69539-051; 63629-8870; 69367-240; 71205-987; 42291-740; 51248-250; 63629-8867; 63629-8868; 65862-878; 67877-527; 0527-1934; 71205-583; 72205-020; 53747-067; 57438-8096; 62512-0054; 64552-4022; 64552-4086; 65372-1158; 67835-0018; 31722-028; 35561-286; 50228-427; 50228-428; 60505-4703; 69238-1308; 69367-296; 71205-539; 71205-559; 71205-561; 71205-934; 51407-471; 68462-387; 69844-047; 69844-048; 70518-3156; 14501-0053; 36974-0071; 46708-193; 65862-879; 29300-329; 46708-192; 51248-150; 63629-8532; 71205-540; 72205-021; 72606-009; 53104-7705; 59285-006; 27241-038; 29300-328; 31722-027; 68462-386; 69367-239; 71205-986; 72606-010; 66039-858; 27241-037
UNII KKA5DLD701
Synonyms Solifenacin Succinate | Succinate, Solifenacin | Quinuclidin-3'-yl-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate monosuccinate | YM905 | YM 905 | 905, YM | Vesicare | Solifenacin | 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-1-phenyl-,1- azabicyclo(2.2.2)oct-3-yl ester, (R-(R*,S*))-
Chemical Information
Molecular Formula C27H32N2O6
CAS Registry Number 242478-38-2
SMILES C1CN2CCC1C(C2)OC(=O)N3CCC4=CC=CC=C4C3C5=CC=CC=C5.C(CC(=O)O)C(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain upper07.01.05.003--
Alanine aminotransferase13.03.04.002---
Anaphylactic reaction10.01.07.001; 24.06.03.006--
Angioedema10.01.05.009; 22.04.02.008; 23.04.01.001---
Aspartate aminotransferase13.03.04.008---
Confusional state17.02.03.005; 19.13.01.001--
Constipation07.02.02.001--
Cough22.02.03.001--
Delirium19.13.02.001--
Depression19.15.01.001--
Dermatitis exfoliative10.01.01.004; 23.03.07.001--
Dizziness02.11.04.006; 17.02.05.003; 24.06.02.007--
Dry eye06.08.02.001--
Dry mouth07.06.01.002--
Dyspepsia07.01.02.001--
Dysphonia17.02.08.004; 19.19.03.002; 22.12.03.006--
Electrocardiogram QT prolonged13.14.05.004--
Erythema multiforme10.01.03.015; 23.03.01.003--
Fatigue08.01.01.002--
Gamma-glutamyltransferase13.03.04.022---
Gastrooesophageal reflux disease07.02.02.003--
Glaucoma06.03.01.002--
Hallucination19.10.04.003--
Headache17.14.01.001--
Hyperkalaemia14.05.03.001--
Hypersensitivity10.01.03.003--
Hypertension24.08.02.001--
Ileus07.13.01.001--
Influenza11.05.03.001; 22.07.02.001---
Liver disorder09.01.08.001---
The 1th Page    1 2    Next   Last    Total 2 Pages